Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva (NYSE: VEEV) announced on March 10, 2026 the acquisition of Ostro, a brand engagement platform for life sciences, for approximately $100 million in cash plus long-term equity retention grants. Ostro will operate as an independent unit led by CEO Chase Feiger and will integrate over time with Veeva Commercial Cloud.
Ostro provides AI-driven, MLR-approved conversational responses and engagement analytics to help patients and doctors get compliant answers in real time.
AOP Health is standardizing on Veeva Industry Cloud for Life Sciences (NYSE: VEEV) across development, quality, commercial, and data functions to connect R&D, quality, commercial, and data on a single Vault platform. The move aims to streamline operations, eliminate silos, strengthen quality and safety, and accelerate global growth and time-to-patient.
The collaboration covers Veeva Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud and is positioned to enable closer cross-team collaboration across sales, marketing, medical, clinical, regulatory, and safety.
Veeva (NYSE: VEEV) reported fiscal 2026 total revenues of $3,195.3M, up 16% year‑over‑year, and Q4 revenues of $836.0M, up 16%.
Operating income rose to $916.4M for the year (up 33%) and fiscal year net income reached $908.9M (up 27%). The company provided FY27 non‑GAAP guidance and said it is advancing industry AI and customer adoption.
Veeva (NYSE: VEEV) announced that more than 125 customers are live on Vault CRM across the U.S., Europe and Japan, including multiple top‑20 biopharma companies. With the availability of Veeva AI, Veeva says it is accelerating the industry's shift to agentic CRM.
Veeva updated the end‑of‑support date for legacy Veeva CRM from September 2030 to end of December 2029. Vault CRM is part of the Vault CRM Suite, which also includes Events Management, Service Center, Campaign Manager, and Patient CRM.
Veeva Systems (NYSE: VEEV) will release fiscal 2026 fourth quarter and full year results for the period ended January 31, 2026, after market close on March 4, 2026.
The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on March 4; prepared remarks are expected at 1:05 p.m. PT (4:05 p.m. ET), and a replay will be available on the investor website.
Veeva Systems (NYSE: VEEV) announced that 13 of the top 20 biopharmas have standardized globally on Veeva Link Key People to enhance customer engagement and supply structured datasets for AI. The product added 38 new customers, and 3 top-20 biopharmas became global standards in the past year.
Link Key People is part of Veeva Data Cloud and uses Veeva's Common Data Architecture to connect Link with OpenData, HCP 360, Compass, AI-powered summaries, personalized notifications, and a high-speed Link Direct Data API for analytics and model feeding.
Veeva (NYSE: VEEV) announced Veeva eSource, a new SiteVault application to eliminate paper at clinical sites and streamline data flow from EHR to EDC. The solution offers direct trial data capture, EHR integration, bidirectional EDC integration, an open API, and aims to remove source data verification work. Early adopter availability is planned for second half of 2026 and requires SiteVault CTMS at the site.
Veeva (NYSE:VEEV) highlighted findings from the State of AI in Consumer Goods Report dated January 27, 2026, showing AI-readiness is a top priority for CPG companies.
Key findings: 82% of respondents are consolidating systems to unified platforms for standardized data; 72% are using, preparing, or planning agentic AI for manufacturing; main barriers include compliance/security and cost (both 60%) and integration complexity (58%).
Veeva Systems (NYSE: VEEV) will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco. Brian Van Wagener, CFO, will present on Tuesday, January 13, 2026 at 1:30 p.m. PT. The presentation will be webcast live and an archived webcast will be available on Veeva's investor relations website.
BioMarin (NASDAQ: BMRN) and Veeva Systems (NYSE: VEEV) announced a long-term enterprise agreement on January 8, 2026 to expand their existing relationship.
The partnership aims to increase speed, agility and operational efficiency in developing and commercializing therapies by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products, and to optimize the healthcare professional and patient experience. Company leaders highlighted the collaboration's role in accelerating access to transformative medicines globally.